THE ROLE OF PROBIOTICS IN THE TREATMENT OF HELICOBACTER PYLORI ASSOCIATED DISEASES
Helicobacter pylori (Hp) is a widespread gram-negative, spiral microorganism with flagella that infects the stomach lining. In 1994, the International Agency for Research on Cancer included H. pylori in the list of group 1 carcinogens. Therapeutic options for the treatment of infections caused by H. pylori and aimed at its complete eradication include various combinations of a proton pump inhibitor with two or three antibiotics. This integrated approach is basically associated with a high risk of side effects and non-compliance with treatment. According to the 5 Maastricht Treaty, in order to reduce the risk of side effects on the gastrointestinal tract microbiocenosis and increase the eradication efficacy, it is recommended to complement eradication schemes with probiotics. The ability of certain strains of probiotics to promote eradication during monotherapy has been proved. However, the analysis of findings in subgroups showed that only certain strains including different strains of Lactobacillus could maintain clinical significance. Lactobacillus reuteri DSMZ17648 (Pylopass, a part of the Helinorm trade name) demonstrated a decrease in the level of H. pylori colonization and can be used in eradication schemes to enhance the effectiveness and safety of treatment.